Stephen Schuster, MD, Gives Advice for Treating Aggressive Lymphomas During COVID-19 Pandemic

Article

Stephen Schuster, MD, talked about the benefits of conducting routine visits remotely during the COVID-19 pandemic, allowing doctors to see and treat more patients safely and efficiently.

Stephen Schuster, MD, of Penn Medicine talked about the benefits of conducting routine visits remotely during the COVID-19 pandemic, allowing doctors to see and treat more patients safely and efficiently.

Transcription:

As I said, some of our visits that are very routine can be done remotely. That actually saves time, number 1, and it also reduces traffic to the cancer center and through the waiting room and into the exam room. I think if we can continue to maintain that, we’ll have greater capacity to see patients that need to be seen. People that are being evaluated up front with either a new diagnosis or for evaluation for CAR T, we’ll be able to bring more patients in because our schedule won’t be quite as cluttered with routine follows up, which we can still do, but we can do more efficiently and remotely. We’ll have more space in clinic, more space in our schedules, and probably be able to handle a greater volume of patients.

Related Videos
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.
Related Content